Month: March 2023

SALINAS, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born vertically integrated cannabis company with advanced production capabilities including cultivation, extraction, manufacturing, and distribution, announces audited revenue and operating results for the fourth quarter and fiscal year (ended December 31, 2022). All figures stated are in US Dollars. Fourth Quarter and Fiscal Year Financial Highlights:Revenue generated for the quarter ended December 31, 2022, was $9.3 million; a decrease of 38% from the fourth quarter last year and a 7% sequential increase from the third quarter of 2022. Revenue for the year ended December 31, 2022 was $43.5 million. Sales of self-grown bulk wholesale products increased 42% sequentially to $2.8 million during the quarter...

CALGARY, Alberta, March 30, 2023 (GLOBE NEWSWIRE) — Inventronics Limited (“Corporation”) (IVX:TSX Venture), a designer and manufacturer of enclosures for the telecommunications, electric transmission, cable television and other industries in North America, today announced its 2022 audited annual and unaudited Q4 financial results. For the year ended December 31, 2022, the Corporation reported net earnings of $2,093,000, or 43.4 cents per share, on revenue of $14,245,000 compared to net earnings of $1,890,000, or 41.0 cents per share, on revenue of $9,985,000 for the 2021 fiscal year. For the three months ended December 31, 2022, the Corporation reported net earnings of $252,000, or 5.2 cents per share, on revenue of $2,739,000 compared to net earnings of $303,000, or 6.6 cents per share, on revenue of $1,951,000, for the same period...

FITCHBURG, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Micron Solutions, Inc. (OTCQB: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced financial results for its fourth quarter and fiscal year ended December 31, 2022. For the fourth quarter of 2022, the Company reported $5,553,941 in net sales, as compared to $4,374,960 in the fourth quarter of 2021, a 26.9% increase. This increase is due to stronger results in the company’s core medical market. Net loss for the fourth quarter of 2022 was ($222,563) compared to a net loss of ($928,491) in the fourth quarter of 2021. Gross margin increased to 10.8% in the fourth quarter of 2022, compared...

Recently appointed executive leadership and Board of Directors set to help Company advance its next stage of market growth. DENVER, March 30, 2023 (GLOBE NEWSWIRE) — authID® [Nasdaq: AUID] a leading provider of secure identity authentication solutions today reported financial and operating results for the year ended December 31, 2022. “I am excited about the strength of authID’s digital identity technology. It delivers the enhanced, non-repudiable authentication needed to protect both workforce and consumer applications against identity fraud and cyberattacks associated with compromised passwords,” said CEO Rhon Daguro. “In 2022, our stellar development team delivered our Verified 3.0 platform, secured a perfect score in testing for ISO Level 2 Biometric Presentation Attack Detection, achieved ISO 27001 Certification for Information...

Introduces Q1 2023 Revenue Guidance of Approximately $8 Million and Full Year Fiscal 2023 Revenue Guidance of Between $60-$70 Million PALM BEACH GARDENS, Fla., March 30, 2023 (GLOBE NEWSWIRE) — Molekule Group, Inc. (“Molekule” or the “Company”) (Nasdaq: MKUL), an emerging leader in air purification technology solutions, systems for healthcare and commercial smart building applications, and individual consumer protection, today reported financial results for the three months and year ended December 31, 2022 (“FY 2022”). Fourth Quarter 2022 Operational Highlights and Recent DevelopmentsThe Company’s Pūrgo™ air sanitization device received FDA clearance for the elimination of SARS-CoV-2, with additional testing performed to also confirm elimination of influenza and RSV. Completed the acquisition of Molekule, Inc. on January...

All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and up to 2.7 years in an ongoing Phase 1 trial of INB-100 as of December 9, 2022; Updated clinical data to be reported at the EBMT Annual Meeting in April 2023 INB-200 continued to show durable and favorable responses, with ongoing patients extending beyond 1.5 years and 1.2 years progression free through year-end 2022; currently enrolling patients in Cohort 3; Updated clinical data expected in mid-2023 Presented positive proof-of-concept data demonstrating the potential of INB-300, a next-generation gamma-delta T cell CAR technology, to target tumors while sparing healthy tissue; Additional updates to this program to be reported at the AACR Annual Meeting in April 2023NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — IN8bio,...

Revenue +192% from Q3 2022 Gross profit +256% from Q3 2022 GAAP Net Loss ($539k), pro forma adjusted EBITDA ($170k) Increased pending installations to $47 million as of year-end $8 million of cash, restricted cash, and investments Completed acquisition of SUNation, leading New York installer, tripling revenue run rateMINNETONKA, Minn., March 30, 2023 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (NASDAQ:PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced select financial results for the fourth quarter ended December 31, 2022. Results reflect a partial quarter of contribution from SUNation, the acquisition of which closed on November 9, 2022. Pineapple CEO Kyle Udseth commented, “What a difference a year makes. We entered 2022 as a small private company with big...

Conference Call and Webcast to be held at 8:00 AM ET on Friday, March 31, 2023 BRANFORD, Conn., March 30, 2023 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced its financial results for the year ended December 31, 2022. The company will host a conference call on Friday, March 31, 2023 at 8:00 a.m. Eastern Time to discuss in greater detail its financial and operating results for 2022. John Villano, CPA, the company’s Chief Executive Officer, stated: “2022 was another record year for our company with revenue of $52.3 million and net income attributable to common shareholders of $17.2 million. Earnings per share was $0.46 per share compared to $0.44 for the prior year. Further we achieved approximately $20.2 million of non-GAAP adjusted earnings or $0.53 per share in earnings, reflecting the strength of our...

Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to be completed in 2023 Topline results from the Phase 3 clinical program of DFD-29 to treat papulopustular rosacea expected in the first half of 2023; NDA submission expected in the second half of 2023 MIAMI, March 30, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising...

– Fourth Quarter and Full Year 2022 Cannabinoid Revenue Increased 71% and 90%, Respectively; Total Annual Revenue Growth was 16% Year-over-Year – – Steady Cost Reductions and Portugal Wind-Down Expected to Drive Production, Cost, and CapEx Efficiencies – – Announces Financial Outlook and Key Focus Markets for 2023 – TOCANCIPÁ, Colombia, March 30, 2023 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2022. All financial information is provided in US dollars unless otherwise indicated. “2022 was a transformational year for Clever Leaves as we executed...